Rat-Mouth here says the same thing on other small biotech boards...
Think it's all cut and paste soiled short #$%$.
Ya know, you guys don't seem all that sympathetic to the sordid soiled shorts.
A drop in the SP is common after the IPO.
Once the costs and reorganization of listing is absorbed, they often start to climb.
1000s of hardworking American artists and crafts folk make all or part of their living on ETSY.
You are just a no-count short-mouth.
Nasty drugs that caused serious body pain, giant nausea and so on
saved my life from the cancer that had spread to my lungs.
That's often how it is for effective drugs for life threatening diseases.
Your arguments are childish...Just another hollow short mouth.
Fred...They have the routes to grow all laid out in front of them...But they've become timid and have abandoned their vision.
All we see from them is small, incremental advances, and darned few of them.
We need to automate a bunch of their surgical functions, build software that will allow surgery on a beating heart, incorporate the newer NOVADAQ (SP) visualization tech,move into other surgical specialties,, branch into other micro manipulation fields, scale up their tech for remote operations in hostile environments and so on.
Arun's expectations and future reality are not the closest of friends.
I have little respect for jolly optimism in the face of serial prior disappointments.
I'm still long, but quailing.
Nope...other than we have been trying to establish the market with seemingly superior technology for some years...years gone by ..Still ticking.
We have a limited period of patent protection and i assumed that it took some years to fund, research, develop, test and run through FDA approval, each and every one of our products. All that takes time off ther patent clock.
I thought that ISRG ( i sidled over here from there) exposure would launch this enterprise and expose it to the profession where it would be selectively adopted by several areas of surgeons.
We should have firmly established our stuff as the prevailing standard of care by now.
That has not happened and time passes as my investment loses value and we lose first mover advantage in the face of a giant foe.
Admittedly, i'm temporally challenged, but still...tick, tick, tick.
I lost this race in another glacially advancing biotech investment that had promise and and were too slow to capitalize on it.
Not the references you were hoping for Von..sorry.
Went to their site and it was choked with unsupported claims, hype and distractions...never mind
Those dilutions are an inescapable part of investing in a clinical stage biotech.
Momentum is transient and only means something to day traders..screw 'em.
the dilutions are planned months in advance and the CEO had no way to anticipate the momentum.
If we don't have the funds to forward our trials and R&D..we are a dead issue.
I certainly expected them to panic and capitulate long ago...Stubborn suckers!
Expect more FUD.